ClinicalTrials.gov
ClinicalTrials.gov Menu

Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH (LASERLESS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02976012
Recruitment Status : Unknown
Verified November 2016 by Dennis M. Marcus, M.D., Southeast Retina Center, Georgia.
Recruitment status was:  Recruiting
First Posted : November 29, 2016
Last Update Posted : November 29, 2016
Sponsor:
Information provided by (Responsible Party):
Dennis M. Marcus, M.D., Southeast Retina Center, Georgia

Brief Summary:
This is a phase I/II open label, randomized, interventional clinical trial. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) <21 days but >7 days prior to vitrectomy and one intraoperative IAI at end of surgery followed by randomization in a 1:1 ratio into either 4 mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up (q8 week Group) or 2 mandatory postoperative q4weeks IAI followed by mandatory q16 weeks IAI for 52 weeks follow-up (q16 week Group).

Condition or disease Intervention/treatment Phase
Proliferative Diabetic Retinopathy Drug: Aflibercept Procedure: Endolaserless Vitrectomy Phase 1 Phase 2

Detailed Description:

This is a phase I/II open label, randomized, interventional clinical trial. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) <21 days but >7 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery followed by randomization in a 1:1 ratio into either 4 mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up (q8 week Group) or 2 mandatory postoperative q4weeks IAI followed by mandatory q16 weeks IAI for 52 weeks follow-up (q16 week Group).

Follow-up visits occur 1 day and 1-2 weeks, and 4 weeks postoperatively and then every 4 weeks from the first postoperative IAI for 52 weeks. One preoperative visit and every postoperative visit (except day one postoperatively) will include ETDRS Best Corrected Visual Acuity (BCVA), Intraocular Pressure (IOP) measurement, Slit lamp biomicroscopy, Indirect ophthalmoscopy, Heidelberg Spectralis Spectral Domain Optical Coherence Tomography (SD-OCT) (no OCT for preoperative visit) and evaluation for systemic and ocular adverse events. Seven standard field photographs and Optos wide-field fluorescein angiography will be performed at postoperative visits at 4, 16, 28, 40,and 52 weeks. Humphrey visual field (HVF) testing (30-2 and 60-4 test patterns) will be performed at postoperative visits at 4 and 52 weeks. Preoperative B scan echography will be required standard of care(SOC) to assess for macular traction, non-macular traction, retinal detachment and vitreous hemorrhage(VH). Identification of traction macular detachment will exclude the patient from the study.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Endolaserless Vitrectomy With Intravitreal Aflibercept Injection for Proliferative Diabetic Retinopathy-Related Vitreous Hemorrhage (LASER LESS TRIAL)
Study Start Date : June 2016
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : June 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: IAI q8 week Group
Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group ("q8 week Group") where 4 additional mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up. Starting at week 20 in the q8week group eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment
Drug: Aflibercept
. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) <21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.
Other Names:
  • Eylea
  • 2 mg/0.05 mL single use vial for intravitreal injection

Procedure: Endolaserless Vitrectomy
Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage

Active Comparator: IAI q16 week Group
Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q16week Group) where 2 additional mandatory postoperative q4weeks IAI will be followed by mandatory q16weeks IAI for 52 weeks follow-up. Starting at week 12 in the q16 group, eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment.
Drug: Aflibercept
. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) <21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.
Other Names:
  • Eylea
  • 2 mg/0.05 mL single use vial for intravitreal injection

Procedure: Endolaserless Vitrectomy
Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage




Primary Outcome Measures :
  1. • Ocular and systemic safety evaluation for adverse events at any time point through 52 weeks: [ Time Frame: Through 52 weeks from Baseline ]
    Examples include worsened acuity >30 letters, rhegmatogenous or tractional retinal detachment, endophthalmitis, new or increased vitreous hemorrhage, cataract progression or surgery, need for additional vitrectomy or scleral buckle, development of new DME after OCT documentation of absence of DME, systemic thromboembolic events, deaths and systemic serious adverse events at any time point through week 52.


Secondary Outcome Measures :
  1. Mean change in BCVA letter score [ Time Frame: 52 weeks from Baseline ]
    Mean change in BCVA letter score over time through week 52

  2. Mean BCVA letter score [ Time Frame: 52 weeks from Baseline ]
    Mean BCVA letter score over time through week 52

  3. Proportion of eyes with progression of PDR [ Time Frame: Through 52 weeks from Baseline ]
    Proportion of eyes with progression of PDR as defined above at any time point through week 52

  4. Mean OCT CSF thickness [ Time Frame: Through 52 weeks from Baseline ]
    Mean OCT CSF thickness over time through week 52

  5. Proportion of eyes with OCT CSF thickness <300um [ Time Frame: Through 52 weeks from Baseline ]
    Proportion of eyes with OCT CSF thickness <300um at week 52

  6. Proportion of eyes with absence of Optos widefield fluorescein angiographic macular leakage [ Time Frame: Through 52 weeks from Baseline ]
    Proportion of eyes with absence of Optos widefield fluorescein angiographic macular leakage at week 52

  7. Proportion of eyes with absence of active neovascularization [ Time Frame: Through 52 weeks from Baseline ]
    Proportion of eyes with absence of active neovascularization by Optos widefield fluorescein angiography at week 52

  8. Proportion of eyes with absence of active neovascularization [ Time Frame: Through 52 weeks from Baseline ]
    Proportion of eyes with absence of active neovascularization by 7 standard field photography at week 52

  9. Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic macular leakage [ Time Frame: Through 52 weeks from Baseline ]
    Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic macular leakage from baseline angiograms at week 52

  10. Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic neovascularization [ Time Frame: Through 52 weeks from Baseline ]
    Proportion of eyes with unchanged, worsened, or improved fluorescein angiographic neovascularization from baseline angiograms at week 52

  11. Proportion of eyes with unchanged, worsened, or improved fundus photographic DME appearance [ Time Frame: Through 52 weeks from Baseline ]
    Proportion of eyes with unchanged, worsened, or improved fundus photographic DME appearance from baseline photographs at week 52

  12. Mean cumulative score and change for the combined 30-2 and 60-4 HVF test [ Time Frame: Through 52 weeks from Baseline ]
    Mean cumulative score and change for the combined 30-2 and 60-4 HVF test from week 4 to week 52.

  13. Proportion of eyes requiring additional IAI other than mandatory injections [ Time Frame: Through 52 weeks from Baseline ]
    Proportion of eyes requiring additional IAI other than mandatory injections through week 52

  14. Proportion of eye with progression of PDR requiring rescue PRP standard of care [ Time Frame: Through 52 weeks from Baseline ]
    Proportion of eye with progression of PDR requiring rescue PRP standard of care at any time point through 52 weeks

  15. Proportion of eyes requiring PRP or retinopexy [ Time Frame: Through 52 weeks from Baseline ]
    Proportion of eyes requiring PRP or retinopexy through week 52

  16. Proportion of eyes requiring additional vitrectomy [ Time Frame: Through 52 weeks from Baseline ]
    Proportion of eyes requiring additional vitrectomy through week 52

  17. Proportion of enrolled eyes requiring intraoperative endolaser in a PRP pattern at the time of initial vitrectomy [ Time Frame: Through 52 weeks from Baseline ]
    Proportion of enrolled eyes requiring intraoperative endolaser in a PRP pattern at the time of initial vitrectomy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Adults age >18 years with Diabetes Mellitus
  2. PDR- related vitreous hemorrhage and not of another cause
  3. BCVA Vision LP or better
  4. Investigator determination that vitrectomy indicated for PDR-related vitreous hemorrhage
  5. Willing and able to comply with clinic visits and study-related procedures
  6. Provide HIPPA and signed informed consent prior to any study procedures

Exclusion Criteria:

  1. A condition per investigator opinion, would preclude participation in the study (unstable medical status, cardiovascular disease, glycemic control, inability to follow up etc.)
  2. Participation in an investigational trial within 30 days of enrollment
  3. Known allergy to IAI
  4. Systemic anti-VEGF or pro-VEGF treatment within 4 months of enrollment
  5. For women of childbearing age, pregnant or lactating or intending to become pregnant within the next 3 years
  6. History of PRP or peripheral retinal cryopexy or peripheral retinopexy for any reason in the study eye
  7. History of vitrectomy in the study eye
  8. History or evidence for rhegmatogenous retinal detachment in the study eye
  9. Evidence of traction retinal detachment involving or threatening central macula in the study eye
  10. Exam evident of external ocular infection (i.e. conjunctivitis, significant blepharitis, chalazion etc)
  11. Intravitreal anti-VEGF injection in the study eye <4weeks from enrollment.
  12. Pregnant or breast-feeding women
  13. Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly) *Contraception is not required for men with documented vasectomy. **Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02976012


Contacts
Contact: Dennis M Marcus, MD 706-650-0061 dmarcus@southeastretina.com
Contact: Siobhan Ortiz 706-650-0061 siobhan@southeastretina.com

Locations
United States, Georgia
Southeast Retina Center, PC Recruiting
Augusta, Georgia, United States, 30809
Contact: Siobhan Ortiz    706-650-0061      
Contact: Dennis M Marcus, MD    706-650-0061    dmarcus@southeastretina.com   
Sponsors and Collaborators
Southeast Retina Center, Georgia
Investigators
Principal Investigator: Dennis M Marcus, MD Southeast Retina Center, PC

Responsible Party: Dennis M. Marcus, M.D., Principal Investigator, Southeast Retina Center, Georgia
ClinicalTrials.gov Identifier: NCT02976012     History of Changes
Other Study ID Numbers: VGFTe-DR-1548
First Posted: November 29, 2016    Key Record Dates
Last Update Posted: November 29, 2016
Last Verified: November 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Dennis M. Marcus, M.D., Southeast Retina Center, Georgia:
Proliferative Diabetic Retinopathy
Aflibercept
Vitreous Hemorrhage

Additional relevant MeSH terms:
Retinal Diseases
Diabetic Retinopathy
Vitreous Hemorrhage
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Eye Hemorrhage
Hemorrhage
Pathologic Processes